- Product line overview
- Technical notes
- Featured kits
- Technology and application overviews
- FAQs and tips
- DNA-seq protocols
- Bioinformatics resources
Neural multiomics Q&A
Increased single-cell sensitivity is a constant goal in the next-generation sequencing field.
In our on-demand webinar, "Scaled, high-fidelity electrophysiological, morphological, and transcriptomic cell characterization," Dr. Brian Lee discussed how scientists in his lab are improving transcriptomic data using Takara Bio's highest sensitivity SMART-Seq technology in their neuronal Patch-seq workflow.
Continue reading for insights from the Q&A session or register to watch the on-demand webinar.
What is the percentage overlap between the clusters and the met space?
Dr. Lee: I don't know the exact percentage of what the overlap is, but we are able to take the framework from our RNA-seq platform and map our cells onto that. What we have found is that when the nucleus is included, we get a nice alignment with particular types, subclasses, and transcriptomic types to the RNA-seq platform.
Can you add any other measurements to Patch-seq, like whole genome amplification or any type of epigenetic information?
Dr. Lee: Epigenetic information is possible, since we have the nucleus. We've recently talked about this, but the effort has not yet started. However, we acknowledge that there are epigenetic mechanisms there that we can use to further classify cell types.
Have you tried to extract physiological features related to the resonant properties of the neurons?
Dr. Lee: Yes, we do. What I showed initially was the three standardized stimulus sets that we run. We also have additional stimulus sets that we run on particular types of neurons; we're always adjusting our stimulus sets too.
How do you maintain the integrity of the RNA? Do you have RNase inhibitor in your patch solution?
Dr. Lee: We do have RNase inhibitors and that was quite critical. When we initially started it, we had quite a bit of degradation. We stepped it up to what was currently used in our RNA-seq pipeline of one unit per microliter for the RNase inhibitor.
Due to the components of the RNase inhibitor, that skyrocketed the osmolarity of our internal solution. When we patched onto a cell, the cells would blow up and swell to 10 times the size. We had to methodically lower the RNase inhibitor and settled down to a 0.5 units per microliter. To do that, we had to offset the potassium gluconate concentration in our solution to maintain the proper osmolarity.
How many cells do you require information for before you consider there's enough data to start drawing conclusions?
Dr. Lee: I think it depends on what type of neuron you're looking at, the diversity of those neurons, and then what modality that you really want to try to incorporate. For example, inter neuron types within the visual cortex, we have six or seven different subclasses and as you saw, 10 15, 20 different met types.
So really to make those, I think that you need hundreds, if not thousands of cells. On the flip side, if we were to go to a subcortical region and we start to see some initial results of the diversity, and the diversity between those types is not as great, then maybe we can make that work with a hundred cells. I think that's something that you have to start evaluating as you collect the data.
Have you found any types of neuron subtypes that aren't amenable to Patch-seq?
Dr. Lee: The Cell paper that we published focused on the visual cortex; this year we're expanding to subcortical regions. As anyone may hypothesize or know from personal experience, the neurons at different parts of the brain are different.
What we've started to realize is that is, at least with a couple of the subcortical regions that we're targeting now (one of them being the nucleus accumbens), the membrane properties are actually different. We have to adjust the parameters such that we're able to extract the nucleus while preserving the somatic membrane. We had a standard set that we use for the cortex, but we've found that that is too strong for some types or maybe too weak for other types.
What are the short-term goals for making improvements in your workflow?
Dr. Lee: The biggest thing that we're working on right now is the rate of morphological recovery. In our paper, figure one shows that this is our lowest rate of being able to retain high-quality fills, so our goal is to hone our technique to improve that. We are good at being able to classify the cell types and obtaining good transcriptomics. We're good at obtaining the appropriate amount of RNA and thanks to the Takara Bio SMART-Seq kiton it.
Any tips for maintaining a clean ePhys rig for Patch-seq experiments?
Dr. Lee: That's one thing we really had to spend a bit of time to do. We invited the folks from molecular biology to look over our rigs to see how suitable they were for obtaining molecular biology information, and they were actually astonished to see how dirty our rigs are compared to a molecular biology wet lab.
They gave us some tips and techniques, and we just tried to be as clean as possible. We wear gloves, we wipe down all surfaces. Anything that we touch, we change gloves multiple times a day. We use ethanol to make sure our hands are clean. We have brought hoods into the ePhys lab. So we have hoods just adjacent to the ePhys rigs. As we collect the data, we're able to quickly bring it to the hood and deposit it and reduce any type of air contamination or RNase contamination.
What does your group at the Allen Institute look for in collaborators?
Dr. Lee: We're open to collaborations and have many of them going on right now. I think we're open to multiple types, grant related or non-grant related. If someone has a specific disease model they want to look at, but they don't have the ability to do thousands of recordings, that's one collaboration we can assist with: identifying the cell types that they're currently looking at in a disease model.
At the same time, we also have collaborations going where we're simultaneously collecting data. We have a grant with a collaboration in Amsterdam and Hungary where they are performing the same experiments and sending us the samples to process. It is definitely a wide range of collaborations that we currently have going in.
High-quality, full-length RNA-seq libraries from single cells (e.g., PBMCs) and nuclei.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2022 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.